Dulaglutide Peptide Therapy
Benefits, Side Effects, Cost & Protocols
Dulaglutide, sold as Trulicity, is a once-weekly GLP-1 receptor agonist for type 2 diabetes treatment. It is also approved for reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or risk factors.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated May 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
Who Is Dulaglutide Best For?
How Dulaglutide Works
Long-acting GLP-1 receptor agonist that mimics incretin hormones to regulate appetite and blood sugar with a weekly dosing schedule.
Dulaglutide FAQ
What is DULAGLUTIDE?
Dulaglutide is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes management. Marketed as Trulicity by Eli Lilly, it offers convenient weekly dosing and has shown cardiovascular risk reduction benefits.
How does DULAGLUTIDE work?
Long-acting GLP-1 receptor agonist that mimics incretin hormones to regulate appetite and blood sugar with a weekly dosing schedule.
Is DULAGLUTIDE legal to buy?
DULAGLUTIDE requires a prescription from a licensed healthcare provider. It is legal to purchase with a valid prescription from authorized pharmacies.
Where can I buy DULAGLUTIDE?
DULAGLUTIDE is available by prescription through compounding pharmacies and telehealth providers. Browse our verified provider directory to find trusted sources.
What category does DULAGLUTIDE belong to?
DULAGLUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of DULAGLUTIDE?
DULAGLUTIDE has been studied for: Blood sugar regulation, Cardiovascular risk reduction, Once-weekly dosing, Weight management support. Once-weekly GLP-1 agonist; primarily for diabetes management. Marketed as Trulicity.
Key Studies
1,229 total on PubMed0Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
Nicholls SJ, Bhatt DL, Buse JB et al
Am Heart J · Am Heart JPhase 3
SURPASS-CVOT design comparing tirzepatide vs dulaglutide on cardiovascular outcomes (recruitment complete, ongoing).
SURPASS-CVOT design comparing tirzepatide vs dulaglutide on cardiovascular outcomes (recruitment complete, ongoing)
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Nicholls SJ, Pavo I, Bhatt DL et al
N Engl J MedPhase 3
Tirzepatide was noninferior to dulaglutide for cardiovascular outcomes (HR 0.92, p=0.003 for noninferiority)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein HC, Colhoun HM, Dagenais GR et al
LancetPhase 3
Dulaglutide reduced major adverse cardiovascular events vs placebo (HR 0.88, p=0.026)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Dulaglutide News
Renoprotective effect of dulaglutide in L-NAME-induced hypertensive nephropathy in rats: insight into the roles of PPAR-gamma and VEGF - Nature
Nature · 6 months ago
Mazdutide Outperforms Dulaglutide in Type 2 Diabetes Trial - EMJ
EMJ · 4 months ago
Enrolling clinical trials: GLP-1 agonist therapy in cystic fibrosis-related glucose intolerance - Penn Medicine
Penn Medicine · 10 months ago
Examining Alternative Effects of GLP-1 Receptor Agonists - the-scientist.com
the-scientist.com · 8 months ago
New Weight Loss Drug Outperformed Existing Treatment in Clinical Trial - ScienceAlert
ScienceAlert · 8 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Dulaglutide with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Dulaglutide.
Take the Quiz →